Company intelligence / Profile preview

GEAR Therapeutics

Pittsburgh, Pennsylvania, USA

Ownership: Private
Development stage: Other

Overview

GEAR Therapeutics is developing gene-edited, antibody-resistant NK cell therapies (GEAR-NK), designed to augment the efficacy and safety of monoclonal antibody-based treatments for hematological cancers by preventing immune cell fratricide, with encouraging preclinical data supporting the platform

Therapeutic areas: OncologyHematologyImmunology
Modalities: Cell therapyGene-edited cell therapyNatural killer cell therapy
Industry: Biotech

Drug pipeline

1 asset

GEAR cell therapy

Preclinical

Partnerships

VyGen-Bio (source/licensor of GEAR technology)NextGenNK (Karolinska Institutet collaboration via VyGen-Bio)

Beyond the preview

Go deeper on GEAR Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GEAR Therapeutics.

Explore the full profile